Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc Breastfeeding

Modern medicine has evolved so much so that sooner or later every breastfeeding mother needs to take it in one form or other. Medication that is present in mothers blood will transfer into her breast milk to some extent. Most drugs do so at low levels and pose no real risk to infants but then there are some exceptions. In This post will discuss whether Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc is safe in breast-feeding or not.

What is Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc used for?


temporarily relieves cough due to minor throat and bronchial irritation as may occur with a cold or inhaled irritants relieves your cough to help you sleep helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves cough associated with the common cold

Brief: Antitussive (Cough Suppressant) Expectorant

Is Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc safe to use while breastfeeding? Can it interfere with growth and development of my kid?

Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc high risk while breastfeeding
Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc consists two active ingredients Codeine phosphate and Guaifenesin and as per our analysis of both we have determined the Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc is unsafe during breastfeeding. We recommend you to check both ingredients below for better understanding of Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc in breastfeeding.

Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc Breastfeeding Analsys


Codeine phosphate while Breastfeeding

Unsafe

CAS Number: 76-57-3

Compound of cough and pain medication. The cytochrome P450-CYP2D6 enzyme catalyzes morphine. It is excreted in breast milk in small amounts, much lower than the dose used for newborns and infants. The plasma levels of infants whose mothers take them are very low, less than usual therapeutic levels and assuming an insignificant relative dose, less than 1.5% (Meny 1993, Naumburg 1988, Findlay 1981), so it was considered safe for use during breastfeeding (Bar-Oz 2003, WHO 2002, AAP 2001, Moretti 2000, Spigset 2000, Mitchell 1999, Meny 1993). However, excessive sedation in the mother or infant may occur if they are rapid metabolizers of codeine to morphine due to an excess of the gene linked to the P450-2D6 enzyme: this occurs in <1% of Chinese, Japanese and Hispanic people; 3% African Americans; 1-10% of Caucasians and 16-29% of North Africans, Ethiopians and Saudis (Halder 2015, Sachs 2013). The genetic diagnosis of this characteristic is not available in usual clinical practice (Madadi, 2011). Codeine through breast milk has been linked to the appearance of neonatal apnea (Naumburg, 1988), drowsiness (Ito, 1993), neurological depression (Madadi, 2008) and, above all, a fatal outcome: a newborn whose mother had this genetic abnormality died at 13 days; the mother was taking 60 mg of codeine twice daily, morphine levels were normal in breast milk, but very high in the child's plasma (Madadi 2007, Koren 2006). Subsequently, the causality of codeine in this case has been called into question (Bateman 2008, Ferner RE 2008, Young 2007). A link has been found between the use of codeine during pregnancy and breastfeeding and the risk of developing neuroblastoma in the infant (Cook, 2004). Because of all this, and with newborns having a limited capacity for opioid elimination (Willmann, 2009) and the existence of more effective alternatives, many authors and institutions advocate completely discouraging its use in infants and breastfeeding mothers (FDA 2017, Al-Adhami 2016, Lazaryan 2015, AEMPS 2015, Sachs 2013, EMA 2013). Other authors advocate cautious use (some even in the case of rapid metabolizers), using the lowest possible effective dose and for no more than 4 days and monitoring for signs of sedation in mother and infant (Royal Berkshire-NHS 2016, Halder 2015, Reece-Stremtan-ABM Protocol#21 2015, Chow 2015, Kelly 2013, UKMi NHS 2013, Rowe 2013, Montgomery-ABM protocol#15 2012, Amir 2011, Madadi 2009, Madadi 2007, FDA 2007). The use of non-steroidal anti-inflammatory drugs (NSAIDs) better controls pain and with fewer side effects than codeine alone or in combination with paracetamol (Palanisamy 2014, Hendrickson 2012, van den Anker 2012, Madadi 2009, Nauta 2009, Willmann 2009), and codeine is not included either in international consensus on the treatment of migraines (Bordini 2016, Worthington 2013). Follow WHO standards for childbirth attendance, reduce cesarean sections and episiotomies, and therefore the need for analgesics in the first few days.

Guaifenesin while Breastfeeding

Low Risk

CAS Number: 93-14-1

It is used as an expectorant, alone or in association with other products. Proofs on its effectiveness are sparse. In some instances, preparations of Guaifenesin may contain alcohol as excipient with a concentration as high as 5%. At latest update, relevant published data on excretion into breast milk were not found. Until more information on this medication is available, other option known to be safer would be recommended, mostly in the post-natal period or in cases of prematurity. If used while breastfeeding, a moderate use with the lowest dose as possible and avoiding those preparations with alcoholic excipient, should be preferred. Because effectiveness is poor and likelihood of side effects does exist, especially in multi-association, the US Agency for Drug Administration (FDA) is currently doing efforts for discontinuation of this and others at-the-counter products, that are formulated for cough relief (Guaifenesin, Dextromethorphan, Phenylephrine, Pseudoephedrine, Brompheniramine, etc.)


Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc Breastfeeding Analsys - 2


Codeine phosphate while Breastfeeding

CAS Number: 76-57-3

Maternal use of codeine during breastfeeding can cause infant drowsiness, central nervous system depression and even death, with pharmacogenetics possibly playing a role.[1][2] Newborn infants seem to be particularly sensitive to the effects of even small dosages of narcotic analgesics. Once the mother's milk comes in, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of oral codeine to 2-4 days at a low dosage with close infant monitoring, especially in the outpatient setting.[2][3][4][5] If the baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness, a physician should be contacted immediately.[6] Excessive sedation in the mother often correlates with excess sedation in the breastfed infant. Following these precautions can lower the risk of neonatal sedation.[7] Numerous professional organizations and regulatory agencies recommend that other agents are preferred over codeine or to avoid codeine completely during breastfeeding;[8][9][10][11][12] however, other opioid alternatives have been studied less and may not be safer.[13]

Guaifenesin while Breastfeeding

CAS Number: 93-14-1

Neither the excretion of guaifenesin in milk nor its effect on breastfed infants have been studied. It is unlikely that with usual maternal doses amounts in breastmilk would harm the nursing infant, especially in infants over 2 months of age. It is best to avoid the use of products with a high alcohol content while nursing.



I am nursing mother and I have already used Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc, what should I do?

We have already established that Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc is unsafe in breastfeeding and breastfeeding while using Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc is not a good idea however if have already used and then breastfed the baby then you shall monitor the behavior and health of baby closely and inform your doctor as soon as possible. In case of emergency please call 911.


My health care provider has asked me to use Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc, what to do?

If your doctor knows that you are breastfeeding mother and still prescribes Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc then there must be good reason for that as Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc is considered unsafe, It usually happens when doctor finds that overall advantage of taking outweighs the overall risk.


If I am using Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc, will my baby need extra monitoring?

Yes, Extra monitoring is required if mother is using Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc and breastfeeding as it is considered unsafe for baby.


Who can I talk to if I have questions about usage of Codeine Phosphate And Guaifenesin | Bishop Pharma, Llc in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week

Drug Brands with same Active ingredients